Respiratory syncytial virus-parainfluenza virus vaccineAlternative Names: FRSV-HNPIV-3
Latest Information Update: 20 Jul 1998
At a glance
- Originator Pharmacia Corporation; sanofi pasteur
- Class Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Parainfluenza virus infections; Respiratory syncytial virus infections
Most Recent Events
- 20 Jul 1998 No-Development-Reported for Parainfluenza virus infections in USA (Unknown route)
- 20 Jul 1998 No-Development-Reported for Respiratory syncytial virus infections in USA (Unknown route)
- 18 Jan 1995 Preclinical development for Parainfluenza virus infections in USA (Unknown route)